Sharemaestro Newsreel

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

Two AtriCure directors, including Maggie Yuen, sold shares after a strong second quarter where the company reported 13% revenue growth and raised its full-year outlook. Yuen sold 3,500 shares, reducing her direct equity stake by 20%, though the timing of sales by multiple directors …

Kaplan Fox Encourages Investors of Medline Inc. (MDLN) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. (MDLN) following a warning letter from the FDA regarding "significant violations of Current Good Manufacturing Practice regulations" and inadequate cleaning practices. The FDA letter, dated May 28, 2026, led to a …

Ducommun (NYSE:DCO) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen has upgraded Ducommun (NYSE:DCO) stock from a "hold" to a "buy" rating. This upgrade follows Ducommun's strong second-quarter results, where the company surpassed EPS and revenue expectations, and multiple other analysts have also raised their price targets on the stock. Despite …

Cooper Companies Inc (COO) Stock News Today

This page provides current stock information for Cooper Companies Inc (COO), including its latest stock price, market capitalization, and P/E ratio. It indicates that more news and analysis for the company's stock is expected soon. The page also features a general disclaimer about investment …

Raymond James raises ICU Medical stock price target on revenue growth

Cognition Therapeutics (NASDAQ:CGTX) Releases Earnings Results, Beats Estimates By $0.02 EPS

Cognition Therapeutics (NASDAQ:CGTX) reported a quarterly loss of $0.04 per share, surpassing analysts' consensus estimate by $0.02. Following the earnings release, CGTX shares declined by $0.05 to $1.08. Institutional investors hold 43.35% of the stock, and analysts maintain a "Moderate Buy" consensus rating with …

ICU Medical, Inc. Stock 12‑Month Price Target Raised to $194.14, Implies 17% Upside

Seven analysts have raised the average 12-month price target for ICU Medical, Inc. (ICUI) stock from $176.43 to $194.14, with individual forecasts ranging from $187 to $200 per share. This new target suggests a potential upside of approximately 17% based on the August 6th …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Avantor, Inc. (AVTR) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avantor, Inc. (NYSE: AVTR) securities. The investigation focuses on whether Avantor and its officers engaged in corporate wrongdoing, specifically for investors who bought securities prior to March 5, 2024, and …

AtriCure Inc (ATRC) Stock News Today

This article provides the latest stock news for AtriCure Inc (ATRC), detailing its current stock price, market capitalization, and performance metrics. It also highlights that more news, earnings, analyst ratings, and key developments will be available soon.

Femasys Inc. Announces $30 Million Private Placement Led by Nantahala Capital With Up to $60 Million in Potential Warrant Proceeds

Femasys Inc. announced a $30 million private placement led by Nantahala Capital, involving the sale of common stock and pre-funded warrants along with accompanying warrants. The financing could yield up to an additional $60 million if all warrants are exercised for cash, with some …

Delcath Systems (NASDAQ:DCTH) Issues Earnings Results, Beats Estimates By $0.16 EPS

Delcath Systems (NASDAQ:DCTH) reported stronger-than-expected Q2 earnings, with EPS of $0.07 against an estimated loss of $0.09, and revenue reaching $29.13 million, surpassing expectations. The company raised its full-year 2026 revenue guidance to $104 million-$108 million, driven by a 21% year-over-year increase in HEPZATO …

Immix Biopharma (NASDAQ:IMMX) Announces Quarterly Earnings Results

Immix Biopharma (NASDAQ:IMMX) announced its quarterly earnings, reporting an EPS of ($0.18), which slightly missed the consensus estimate of ($0.17). Following the news, shares dropped 3.4% to $9.72, significantly below the average analyst target price of $20.71. Despite the earnings miss, the company holds …

Teleflex Inc.: To Repurchase Aggregate $250M of Co's Common Stock>TFX

Teleflex Inc. announced its intention to repurchase an aggregate of $250 million of its common stock. This move is typically seen as a way for a company to return value to shareholders and can indicate management's confidence in the company's future prospects. The repurchase …

Daxor Corp (DXR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Daxor Corp (DXR), detailing analyst ratings and price targets. Based on input from two analysts, the consensus is a "Buy" trend with a target price of $22.50, representing a potential upside of 113.88%. The highest forecast is …

BioLife Solutions (BLFS) Is Up 7.2% After Swinging From Loss To Q2 Profit - What's Changed

BioLife Solutions (BLFS) reported a significant turnaround in Q2 2026, swinging from a net loss of US$15.84 million to a net income of US$45.10 million, with sales increasing to US$28.47 million. This improved financial performance follows the announcement of a US$1.6 billion acquisition by …

Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and ...

This article first appeared on GuruFocus. Revenue: $5 billion, up 4.4% on an FX-neutral basis. Adjusted Operating Margin: 24.9%, down 130 basis points versus the prior year. Adjusted Gross Margin: 54.3%, down 100 basis points versus the prior year. Adjusted EPS: $3.23, up 4.9%. …

Price to earnings forward of Femasys Inc. – NASDAQ:FEMY

This article provides the "Price to earnings forward" metric for Femasys Inc. (NASDAQ: FEMY). It is presented within the context of TradingView's financial data offerings, indicating the company's stock market information. The content itself is very minimal, focusing solely on this single financial data …

Pulse Biosciences (NASDAQ:PLSE) Trading Up 15.7% - Should You Buy?

Pulse Biosciences (NASDAQ:PLSE) experienced a 15.7% surge in its stock price, reaching approximately $44.26, despite a 51% drop in trading volume. The company holds a "Moderate Buy" consensus from analysts, though its average price target of $32.33 is below the current share price. This …

EMBC Deadline: EMBC Investors with Losses in Excess of $100K Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit

The Rosen Law Firm is reminding investors who purchased Embecta Corp. (NASDAQ: EMBC) common stock between November 25, 2025, and May 4, 2026, of the August 17, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Embecta made false and …

Anteris Technologies Global Corp (AVR) Stock News Today

This article provides current stock information for Anteris Technologies Global Corp (AVR), including its stock price, market capitalization, and a note about upcoming news. As of the close on August 7th, the stock was trading at $8.910, up 6.58%. The article indicates that more …

ResMed (RMD) Stock Drops As Margin Strength Meets Higher Expectations

Zentek Ltd (ZTEK) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Zentek Ltd (ZTEK), detailing future EPS and revenue growth estimates. It includes current stock information, market capitalization, and a peer comparison with other biotechnology and medical research companies. The financial forecasting section covers EPS, Revenue, and Net …

Merit Medical (MMSI) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Martha Aronson Executive Vice President and Chief Financial Officer - Raul Parra Chief Legal Officer and Corporate Secretary - Brian Lloyd Full …

DENTSPLY SIRONA Inc. Stock 12‑Month Price Target Raised to $13.7, Implies 4% Upside

Analysts have raised DENTSPLY SIRONA Inc.'s average 12-month price target from $13.53 to $13.7, suggesting a 4% potential upside based on its closing price on August 6th. The consensus rating from 19 analysts remains "Hold," with a breakdown of 4 Buys, 13 Holds, and …

ResMed Price Target Raised to $244.00/Share From $234.00 by RBC Capital

RBC Capital has increased its price target for ResMed (RMD) shares to $244.00, up from the previous target of $234.00. This adjustment maintains an "Outperform" rating on the stock. The new price target suggests a potential upside from its last closing price of $219.00.

DENTSPLY SIRONA (XRAY) Could Be 11% Undervalued As Earnings Beat Meets Weak Returns

Bausch + Lomb (BLCO) Q2 2026 Earnings Call Transcript

BioNano Genomics Inc (0A4K) Q1 2026 Earnings Report - Results, Call & Slides

BioNano Genomics Inc. (0A4K) reported its Q1 2026 earnings, beating analyst expectations with an EPS of -$0.76 against a consensus of -$0.88 and revenue of $6.69M, surpassing the expected $6.57M. The company highlighted positive operational developments including record flow cell sales, strong consumables growth, …

BioLife Solutions (BLFS) Stock Price Ignores A Sharp Turn To Profit

Azenta, Inc. $AZTA Stake Cut by Quantinno Capital Management LP

Quantinno Capital Management LP significantly reduced its stake in Azenta, Inc. (NASDAQ:AZTA) by 63.3% in the first quarter, selling over 391,000 shares and retaining 226,690 shares valued at approximately $4.79 million. Despite this, Azenta recently surpassed quarterly earnings expectations, reporting an adjusted EPS of …

Becton Dickinson (BDX) Stock Shrugs Off Profit Strength As Tariffs Bite

Becton Dickinson (BDX) stock saw a minimal slip of 0.1% despite strong adjusted earnings per share of US$3.23 and a solid operating margin of 24.9% in its Q3 2026 earnings report. While the company's "New BD" strategy is showing positive signs like FX-neutral revenue …

ICU Medical (ICUI) Stock Climbs As Margin Gains Sharpen The Debate

Lazard Asset Management LLC Makes New Investment in Avantor, Inc. $AVTR

Lazard Asset Management LLC has made a new investment in Avantor, Inc. (NYSE:AVTR), purchasing 81,813 shares valued at approximately $641,000 during the first quarter. Institutional investors collectively own 95.08% of the company, with other major funds also adjusting their positions. Avantor recently exceeded quarterly …

A Look at Avantor Inc (AVTR) After 3.1% Gain -- GF Value $16.96 vs Price $13.59

Avantor Inc (AVTR) shares increased by 3.1% to $13.59, trading below its GF Value™ of $16.96, suggesting it is 19.9% undervalued. Despite being cash-flow-negative, the company holds an above-average GF Score™ of 67/100, with strong valuation but weak growth. Insider buying activity of $0.1M …

AtriCure (ATRC) director Maggie Yuen reports sale of 3,500 shares

AtriCure director Maggie Yuen sold 3,500 shares of Common Stock on August 5, 2026, at a weighted average price of $38.42 per share, totaling approximately $134,470. The shares were sold in multiple trades ranging from $38.37 to $38.43, and she now directly holds 14,015 …

AtriCure Inc (ATRC) Director Karen Prange Sells 3,564 Shares

AtriCure Inc (ATRC) Director Karen Prange sold 3,564 shares of the company on August 5, 2026, for a total value of approximately $138,283. This sale contributes to a pattern of 14 insider sells and no buys over the past year. The stock is currently …